AzTrials
AzTrials

Heart FailureNCT05980585

Assessment of Heart Failure (HF) At-Home Management Solution ADI Cardio Pulmonary Monitoring System (CPM)

A study testing CPM Device in people with Heart Failure, run by Analog Device, Inc. at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study is meant primarily to assess the deployment of the ADI CPM System in a clinical setting and determine interoperability of the CPM System within existing care pathways for patients with CHF. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Heart Failure
What is being tested?
CPM Device
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2 participants
Where
1 siteUnited States
Study dates
20 Apr 2022to 24 Jun 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • NYHA Class III-IV HF
  • NYHA Class II HF patients with elevated BNP levels (BNP>100 pg per mL) NYHA Class II HF patients with elevated NT-proBNP levels (NT-proBNP>400 pg per mL)
  • HF Patients with at least one Worsening HF event (in /out-patient) in past 12 months
  • HF patients with Acute Renal Failure or Chronic Kidney Disease
  • HF patients with Chronic Obstructive Pulmonary Disease (COPD)
  • HF patients currently on 40 mg or more of Furosemide /

Who cannot join

  • Under age 60
  • End Stage Renal Disease
  • Patients with severe COPD (GOLD stage III or IV)
  • Limited mobility preventing application of device
  • Cognitive impairments that would limit the application and proper use of the device
  • Skin allergies or skin sensitivities to silicone-based adhesives
Show all 10Show fewer
  • Pregnancy
  • Skin breakdown on the left chest or breast area
  • Not willing to shave chest hair if needed to apply device
  • No cellular coverage (Patient's Home)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Baptist Health

    Jacksonville Beach, Florida, 32250

Other trials in United States

About this study

This study is meant primarily to assess the deployment of the ADI CPM System in a clinical setting and determine interoperability of the CPM System within existing care pathways for patients with CHF. In this initial study the CPM System will not be used to determine or support clinical decision making however post deployment the clinical study team will review patient HF events and changes in treatment during the course of the deployment and compare to the data generated by the CPM System during the study to determine the accuracy of the patient generated data as a basis for designing a more comprehensive "interventional study" to determine clinical and financial efficacy of the CPM System.

Read the detailed description

Patients will be recruited and begin the study as they are identified and consent to the study. Recruiting will end either by a designated date set at the initiation of the study or when 30 patients have been enrolled in the study.

The duration of the study for each patient will be approximately 60 days beginning with the baseline/initial visit and concluding 30 days after the patient has completed device use. The patient will use the device given to the once a day during the first 60 days the study and following that time patient records will be reviewed retrospectively for CHF events for the 60 days plus an additional 30 days after their last measurement. Each patient will also receive weekly calls from the research team to check in on device functionality and assure adherence to the protocol.

At visit 1, the start of the study, baseline information will be collected, importantly including accurate weight and notes about congestion and fluid buildup. The study will be re-described to the participant. The research team will then set up the device for the individual patient by making adjustments (as needed) to address patient specific anatomy), ensuring that the sensors are all contacting the appropriate chest areas, and confirming the measurements on the CPM Web application. The patient will be shown how to apply and replace the adhesive on the device, how to position the device, how to take a measurement with the device, and how to store the device on the Base Station. The trained provider will then register the baseline reading for the CHF device using the CHF Mobile App.

Informational materials about using the device, refreshing adhesives, and meanings of LEDs and chimes on the device will also be given to the patient. The patient will be instructed to follow the normal regimen prescribed by their by their physician, but to add taking a measurement with their CPM at the same time each day (preferably when they first wake up).

Between visits, caregivers will not have any access to the data being collected on the CHF Device. They should perform their usual standard of care on these patients. Participants will also receive calls from the research team to check in about the progress of the study (i.e., if protocols are being followed correctly, if the CPM device is working properly, and if adherence is satisfactory. This check-in, conversation topics should focus on any ease-of-use issues and address any compliance-based issues.

The ADI team will have access to data (without any patient identifying information) throughout the course of the trial, including adherence rates of patients. The sponsors will reach out to the study team if a specific patient is found to have missed 2 days in a row of measurements. The research team will contact patients directly if there is a continued trend towards non-compliance.

If a participant is having technical difficulties using the CPM System, the research team in conjunction with ADI will provide direct (in office) or remote assistance or replace existing equipment as necessary.

On visit 2, which will take place at the end of the 60 days, the research team will make arrangements for the patient to return to the office for a check-up and return the device (the same tests as described in the "physical examination" section including b lines/comet tails, dyspnea scale, etc.). Patients will also be asked about their perception on "ease of use", impact on day-to-day activities, and overall satisfaction with the CPM system. Thirty days following the last measurement the study team, will review the patients records for all HF related events and treatment changes.

Conditions
Heart Failure
Being tested
CPM Device
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CPM DeviceDevice

    Daily use of the CPM wearable device

Study groups in NCT05980585
Study groupRoleWhat they receive
Study GroupExperimentalThe Study group will use the CPM device once daily (in the morning) for 60 days.
Receives: Device: CPM Device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Interoperability of CPM system

    patient satisfaction with system obtained through survey questions; ease of use, impact and satisfaction; scale of 1-7 used with 1 being negative and 7 being positive, impact on daily life obtained though Minnesota Living with Heart Failure questionnaire

    Measured: 60 days

Secondary outcomes (1)
  1. Correlation of device data and clinical outcomes

    Retrospective review of data to determine correlation of patient specific device measurements (such as increase/decrease in specific device parameters) with heart failure events. Measurements include thoracic impedance, respiration rate (RR), heart rate (HR), relative tidal volume (rTV), RR variability, HR variability, RR/rTV, QRS width, QTc width, presence of atrial fibrillation, and diastolic heart sound strength

    Measured: 90 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2023
  2. Study start20 Apr 2022
  3. Primary completion30 Apr 2022
  4. Study completion24 Jun 2024

Why it stopped: Terminated due to operational considerations

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Model description
The study looks at a single group of patients that uses the CPM Device
Masking
None (open label)
Enrolment
2 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05980585
Sponsor's protocol ID
OBS-BAPTISTJAX
Status last verified
Aug 2026
First submitted
26 Jul 2023
Last updated
19 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing CPM Device in people with Heart Failure, run by Analog Device, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Terminated due to operational considerations). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Interoperability of CPM system (time frame: 60 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in